#news #biotech Sarepta’s DMD gene therapy fails phase 2 motor function test, sinking stock

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Sarepta’s DMD gene therapy fails phase 2 motor function test, sinking stock .Sarepta’s DMD gene therapy fails phase 2 motor function test, sinking stock
ntaylor
Fri, 01/08/2021 – 05:34

from FierceBiotech: Biotech https://ift.tt/3osi4D3